Assembly Biosciences’ (ASMB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report released on Monday morning,Benzinga reports. They currently have a $50.00 price target on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on ASMB. Guggenheim increased their target price on shares of Assembly Biosciences from $31.00 to $39.00 and gave the company a “buy” rating in a research report on Monday, September 8th. Citizens Jmp assumed coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. JMP Securities began coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 target price on the stock. Finally, Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Assembly Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Assembly Biosciences Stock Up 3.1%

Shares of NASDAQ:ASMB opened at $33.73 on Monday. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $39.71. The company’s 50 day moving average price is $33.63 and its two-hundred day moving average price is $25.78. The firm has a market cap of $533.61 million, a PE ratio of -7.04 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. On average, research analysts expect that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Trading of Assembly Biosciences

Institutional investors have recently made changes to their positions in the company. Farallon Capital Management LLC purchased a new position in shares of Assembly Biosciences during the 3rd quarter valued at $31,426,000. RA Capital Management L.P. bought a new stake in Assembly Biosciences in the 3rd quarter valued at about $26,122,000. Commodore Capital LP purchased a new stake in Assembly Biosciences during the third quarter valued at about $25,600,000. Parkman Healthcare Partners LLC bought a new position in Assembly Biosciences during the third quarter worth about $6,425,000. Finally, Vanguard Group Inc. boosted its position in Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares during the period. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.